HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antiplatelet Premedication for Stent-Assisted Coil Embolization of Intracranial Aneurysms: Low-Dose Prasugrel vs Clopidogrel.

AbstractBACKGROUND:
The use of antiplatelet medications to prevent thrombosis in the treatment of cerebral aneurysms with stents has become widely emphasized.
OBJECTIVE:
To compare low-dose prasugrel with clopidogrel in stent-assisted coil embolization of intracranial aneurysms.
METHODS:
This is a retrospective review of 311 aneurysms from 297 patients who underwent stent-assisted endovascular coil embolization of unruptured intracranial aneurysm between November 2014 and March 2017. Thromboembolic and hemorrhagic adverse events were compared between 207 patients who received low-dose prasugrel (PSG group) and 90 patients who received clopidogrel (CPG group).
RESULTS:
P2Y12 reaction unit (PRU) values were significantly lower in the PSG group (PSG group vs CPG group, 132.3 ± 76.9 vs 238.1 ± 69.1; P < .001); the percentage of inhibition was also statistically higher in the PSG group (54.0 ± 26.0% vs 20.8 ± 18.6%; P < .001). Thromboembolic events occurred less frequently in the PSG group than in the CPG group (0.9% vs 6.4%; P = .01), whereas there was no significant difference in the percentage of hemorrhagic complications (0.5% vs 2.2%; P = .22). In the multivariate analysis, clopidogrel as the antiplatelet medication was the sole significant risk factor for thromboembolism in this series of patients undergoing stent-assisted coil embolization.
CONCLUSION:
Use of low-dose PSG as an antiplatelet premedication is quick, effective, and safe for stent-assisted coil embolization of unruptured intracranial aneurysms. Prasugrel premedication significantly lowered the frequency of thromboembolic events without increasing the risk of hemorrhage.
AuthorsHyun Ho Choi, Jung Jun Lee, Young Dae Cho, Moon Hee Han, Won-Sang Cho, Jeong Eun Kim, Sang Joon An, Jong Hyeon Mun, Dong Hyun Yoo, Hyun-Seung Kang
JournalNeurosurgery (Neurosurgery) Vol. 83 Issue 5 Pg. 981-988 (11 01 2018) ISSN: 1524-4040 [Electronic] United States
PMID29301051 (Publication Type: Journal Article)
Chemical References
  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Prasugrel Hydrochloride
Topics
  • Adult
  • Aged
  • Clopidogrel (therapeutic use)
  • Embolization, Therapeutic (adverse effects)
  • Endovascular Procedures (adverse effects)
  • Female
  • Humans
  • Intracranial Aneurysm (complications, surgery)
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors (therapeutic use)
  • Prasugrel Hydrochloride (therapeutic use)
  • Premedication (methods)
  • Retrospective Studies
  • Risk Factors
  • Stents
  • Thromboembolism (etiology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: